At a glance
A coenzyme involved in redox reactions and cellular maintenance.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source discusses metabolic biology and limited administration studies. Evidence for a precursor or a laboratory pathway should not be assigned directly to NAD+ injections.[1][8][4]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of NAD+.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 1000 mg · 1 source tables
Standard / Gradual Titration Approach (3 mL = 333.3 mg/mL)
| Week | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 50 mg | 15 units (0.15 mL) |
| Week 2 | 75 mg | 22.5 units (0.225 mL) |
| Weeks 3–8 | 100 mg | 30 units (0.30 mL) |
| Weeks 9–12 | 100 mg | 30 units (0.30 mL) |
| Weeks 13–16 | 100 mg | 30 units (0.30 mL) |
Frequency: Inject once daily subcutaneously. This gradual titration protocol begins at 50 mg daily to assess tolerance, as starting too high can produce adverse reactions such as insomnia, anxiety, or fatigue[4]. Most individuals find doses in the 50–100 mg range well‑tolerated after ramp‑up[5]. The 3.0 mL dilution keeps per‑injection volumes practical and allows for accurate unit measurements on standard insulin syringes.
Additional schedule context & duration
Concise summary of the once‑daily subcutaneous regimen.
- Goal: Support cellular energy metabolism, DNA repair pathways, and mitochondrial function through exogenous NAD+ supplementation[1].
- Schedule: Daily subcutaneous injections for 8–16 weeks with gradual dose titration.
- Dose Range: 50–100 mg daily; start low (50 mg) and increase by ~25 mg weekly as tolerated.
- Reconstitution: 3.0 mL per 1000 mg vial (333.3 mg/mL) for accurate unit measurements.
- Storage: Lyophilized powder frozen at −20 °C (−4 °F); reconstituted solution refrigerated at 2–8 °C (35.6–46.4 °F) for up to 14 days; protect from light.
Suggested daily titration approach for subcutaneous administration.
- Start: 50 mg daily for Week 1 to assess individual tolerance.
- Escalation: Increase by 25 mg in Week 2 (75 mg daily); advance to 100 mg daily by Week 3 if well‑tolerated[4][5].
- Maintenance: Continue at 100 mg daily for Weeks 3–16 (or adjust based on response and tolerability).
- Frequency: Once per day, subcutaneous injection.
- Timing: Any consistent time of day; some users prefer morning administration.
- Site Rotation: Rotate injection sites systematically (abdomen, thighs, upper arms) to prevent tissue buildup.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Allow the lyophilized vial to reach room temperature before opening to minimize moisture condensation.
- Draw 3.0 mL bacteriostatic water (0.9% benzyl alcohol) with a sterile syringe.
- Inject slowly down the vial wall to avoid foaming; do not aim directly at the powder.
- Gently swirl or roll the vial until the powder fully dissolves (do not shake vigorously).
- The resulting solution should be clear and colorless. If discoloration or precipitate appears, discard.
- Label with the reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- Use within 14 days; inspect before each use for clarity.
Note: Each 0.01 mL (1 unit) contains approximately 3.33 mg of NAD+. Example conversions: 50 mg = 15 units; 75 mg = 22.5 units; 100 mg = 30 units.
Storage Instructions
Proper storage is critical to preserve NAD+ stability and potency.
- Lyophilized (Unopened): Store at −20 °C (−4 °F) or below (ideally −80 °C for multi‑year storage) in a dry, dark environment[6]. Minimize moisture exposure as NAD+ powder is hygroscopic.
- Reconstituted Solution: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within approximately 14 days[7]. Keep protected from light (UV exposure degrades NAD+).
- Avoid Freeze–Thaw Cycles: Do not repeatedly freeze and thaw reconstituted NAD+ solution, as this reduces potency.
- Inspection: Before each use, inspect the solution for clarity. A fresh NAD+ solution should be clear and colorless. Discard if discoloration, cloudiness, or precipitate develops.
Materials & quantity planning
Source materials checklist · 1000 mg
Plan based on an 8–16 week daily protocol with gradual titration as outlined above.
-
Peptide Vials (NAD+, 1000 mg each):
- 8 weeks ≈ 6 vials (total 5,075 mg used)
- 12 weeks ≈ 8 vials (total 7,875 mg used)
- 16 weeks ≈ 11 vials (total 10,675 mg used)
-
Insulin Syringes (U‑100, 1 mL):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (6 vials): 18 mL → 2 × 10 mL bottles
- 12 weeks (8 vials): 24 mL → 3 × 10 mL bottles
- 16 weeks (11 vials): 33 mL → 4 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 1000 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
- 03
- 07
Source document
Empower Pharmacy — NAD+ injection (lyophilized): compounding specifications and reconstitution guidance (opens in a new tab)www.empowerpharmacy.com
Back to overview ↑ - 09
Source document
AgelessRx — NAD+ injection clinical overview and administration protocols (opens in a new tab)agelessrx.com
Back to overview ↑ - 11
Source document
Pure Bio Labs — NAD+ vial (500 mg): high‑purity peptide product specifications (opens in a new tab)purebiolabs.com
Back to overview ↑ - 15
Continue exploring
Related topics are not interchangeable compounds or formulations.